Friday, June 19, 2026

pharma · COVID-19 · Cystic Fibrosis · ARCT

Arcturus Therapeutics

Arcturus Therapeutics clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

10285 Science Center Dr, San Diego, California 92121, US HQ
2013 Founded
157 Employees
Public company Type
ARCT · NYSE Ticker
Company details
Status
Public
HQ
10285 Science Center Dr, San Diego, California 92121, US
Founded
2013
Employees
157
Programs
13
Drugs
7
Patents
55
Intelligence · Clinical Programs

Arcturus Therapeutics projects

13 ClinicalTrials.gov programs sponsored by Arcturus Therapeutics.

Arcturus Therapeutics has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine

    Arcturus Therapeutics Holdings

    COVID-19 Vaccines

    phase 3 mab completed

    1 trial
  2. ARCT-2303

    Arcturus Therapeutics Holdings

    COVID-19

    phase 3 mab completed

    1 trial
  3. ARCT-021

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab terminated

    1 trial
  4. ARCT-021 Dose 1

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab completed

    1 trial
  5. ARCT-021 single dose priming

    Arcturus Therapeutics Holdings

    Covid19

    phase 2 mab terminated

    1 trial
  6. ARCT-032

    Arcturus Therapeutics Holdings

    Cystic Fibrosis

    phase 2 small molecule active

    2 trials
  7. ARCT-032-02

    Arcturus Therapeutics Holdings

    Cystic Fibrosis

    phase 2 other active

    1 trial
  8. ARCT-165

    Arcturus Therapeutics Holdings

    COVID-19

    phase 2 mab completed

    1 trial
  9. ARCT-810

    Arcturus Therapeutics Holdings

    Ornithine Transcarbamylase Deficiency

    phase 2 mab completed

    3 trials
  10. ARCT-810

    Arcturus Therapeutics Holdings

    OTC Deficiency

    phase 2 mab active

    1 trial
  11. SARS-CoV-2 mRNA Vaccine ARCT-021

    Arcturus Therapeutics Holdings

    Hematopoietic and Lymphatic System Neoplasm

    phase 2 mab active

    1 trial
  12. ARCT-2138

    Arcturus Therapeutics Holdings

    Influenza, Human

    phase 1 mab completed

    1 trial
  13. ARCT-2304

    Arcturus Therapeutics Holdings

    Influenza, Human

    phase 1 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Arcturus Therapeutics have?

13 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.